• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Plasminogen activator inhibitor (PAI-1) in plasma and platelets.

作者信息

Booth N A, Simpson A J, Croll A, Bennett B, MacGregor I R

机构信息

Department of Medicine and Therapeutics, University of Aberdeen, Scotland.

出版信息

Br J Haematol. 1988 Nov;70(3):327-33. doi: 10.1111/j.1365-2141.1988.tb02490.x.

DOI:10.1111/j.1365-2141.1988.tb02490.x
PMID:3264718
Abstract

The distribution of PAI-1 in the plasma and platelets of normal individuals and of patients with platelet abnormalities was studied. An ELISA, capable of measuring PAI-1 in plasma at 1.5 ng/ml, and a functional assay of t-PA inhibition were used to assay platelet-free plasma (PFP), platelet-rich plasma in which the platelets were lysed (PRP) and serum. The PAI-1 concentration of normal PFP was 21.0 +/- 7.2 ng/ml (mean +/- SD) and those of PRP and serum were 282.6 +/- 68.0 and 270.3 +/- 71.9 ng/ml. The concentration of PAI-1 in PRP was proportional to the platelet count with 0.67 +/- 0.18 ng/10(6) platelets. Patients with thrombocytopenia had approximately normal PAI-1 concentrations in PFP; the extremely low concentrations in serum or PRP reflected the platelet count. A patient with grey platelet syndrome showed a comparable pattern, confirming that PAI-1 occurs in the platelet alpha-granules and indicating that the plasma concentration of PAI-1 is independent of the platelet pool of PAI-1. The median inhibitory activities towards t-PA were 1.6, 8.7 and 8.3 units/ml in normal PFP, PRP and serum respectively. PAI-1 in PFP had a median specific activity (units/mg PAI-1) about 5-fold higher than platelet PAI-1. Plasma and platelets represent two distinct pools of PAI-1, both of which should be considered in studies on the relationship between circulating PAI-1 and thrombotic disease.

摘要

相似文献

1
Plasminogen activator inhibitor (PAI-1) in plasma and platelets.
Br J Haematol. 1988 Nov;70(3):327-33. doi: 10.1111/j.1365-2141.1988.tb02490.x.
2
The platelet and plasma pools of plasminogen activator inhibitor (PAI-1) vary independently in disease.纤溶酶原激活物抑制剂(PAI-1)的血小板池和血浆池在疾病中各自独立变化。
Br J Haematol. 1990 Aug;75(4):543-8. doi: 10.1111/j.1365-2141.1990.tb07796.x.
3
Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease.肝脏疾病中的组织型纤溶酶原激活剂、纤溶酶原激活剂抑制剂及激活剂-抑制剂复合物
J Clin Pathol. 1994 Mar;47(3):214-7. doi: 10.1136/jcp.47.3.214.
4
Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation.纤溶酶原激活物抑制剂1:放射免疫分析法的建立及关于其在静脉阻塞期间和血小板聚集后血浆浓度的观察
Blood. 1987 Nov;70(5):1645-53.
5
Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay.使用基于鼠单克隆抗体的酶联免疫吸附测定法测量生物流体中的纤溶酶原激活物抑制剂1
Blood. 1988 Jan;71(1):220-5.
6
Thrombin Provokes Degranulation of Platelet α-Granules Leading to the Release of Active Plasminogen Activator Inhibitor-1 (PAI-1).凝血酶引发血小板α-颗粒脱颗粒,导致活性纤溶酶原激活物抑制剂-1(PAI-1)释放。
Shock. 2018 Dec;50(6):671-676. doi: 10.1097/SHK.0000000000001089.
7
The potential role of platelet PAl-1 in t-PA mediated clot lysis of platelet rich plasma.血小板纤溶酶原激活物抑制剂-1在组织型纤溶酶原激活剂介导的富血小板血浆凝块溶解中的潜在作用。
Thromb Res. 1993 Aug 15;71(4):289-300. doi: 10.1016/0049-3848(93)90198-w.
8
Different types of plasminogen activator inhibitors in plasma and platelets in pregnant women.孕妇血浆和血小板中不同类型的纤溶酶原激活物抑制剂
Br J Haematol. 1986 Feb;62(2):215-20. doi: 10.1111/j.1365-2141.1986.tb02924.x.
9
Plasminogen activator inhibitors in plasma and platelets from patients with recurrent venous thrombosis and pregnant women.复发性静脉血栓形成患者及孕妇血浆和血小板中的纤溶酶原激活物抑制剂
Thromb Res. 1986 Jun 1;42(5):585-94. doi: 10.1016/0049-3848(86)90337-3.
10
[Study on fibrinolysis and platelet function].[纤维蛋白溶解与血小板功能的研究]
Nihon Rinsho. 1992 Feb;50(2):297-302.

引用本文的文献

1
LncRNA H19 acts as a ceRNA to promote glioblastoma malignancy by sponging miR-19b-3p and upregulating SERPINE1.长链非编码RNA H19作为一种竞争性内源RNA,通过吸附miR-19b-3p并上调丝氨酸蛋白酶抑制剂E1(SERPINE1)来促进胶质母细胞瘤的恶性进展。
Cancer Cell Int. 2025 Jun 19;25(1):217. doi: 10.1186/s12935-025-03868-x.
2
Clot formation and resolution properties of platelets during cold storage for 21 days.血小板在冷藏21天期间的凝血和溶解特性。
Transfusion. 2025 Jul;65(7):1307-1318. doi: 10.1111/trf.18283. Epub 2025 May 16.
3
Impact of Plasminogen Activator Inhibitor-1 Serum Levels and the -675 4G/5G Variant in the SERPINE1 Gene on Systemic Sclerosis in a Mexican Population.
纤溶酶原激活物抑制剂-1血清水平及SERPINE1基因-675 4G/5G变异对墨西哥人群系统性硬化症的影响
Life (Basel). 2024 Aug 23;14(9):1056. doi: 10.3390/life14091056.
4
Role of Perturbated Hemostasis in MASLD and Its Correlation with Adipokines.紊乱止血在代谢相关脂肪性肝病中的作用及其与脂肪因子的相关性
Life (Basel). 2024 Jan 7;14(1):93. doi: 10.3390/life14010093.
5
The intersection of coagulation activation and inflammation after injury: What you need to know.损伤后凝血激活与炎症的交集:你需要了解的内容。
J Trauma Acute Care Surg. 2024 Mar 1;96(3):347-356. doi: 10.1097/TA.0000000000004190. Epub 2023 Nov 13.
6
Ketosis Suppression and Ageing (KetoSAge): The Effects of Suppressing Ketosis in Long Term Keto-Adapted Non-Athletic Females.酮症抑制与衰老(KetoSAge):长期生酮适应的非运动女性抑制酮症的影响。
Int J Mol Sci. 2023 Oct 26;24(21):15621. doi: 10.3390/ijms242115621.
7
Identification of genomic loci regulating platelet plasminogen activator inhibitor-1 in mice.鉴定调控小鼠血小板纤溶酶原激活物抑制剂-1的基因组位点。
J Thromb Haemost. 2023 Oct;21(10):2917-2928. doi: 10.1016/j.jtha.2023.06.018. Epub 2023 Jun 25.
8
All tangled up: interactions of the fibrinolytic and innate immune systems.错综复杂:纤维蛋白溶解系统与先天免疫系统的相互作用。
Front Med (Lausanne). 2023 Jun 2;10:1212201. doi: 10.3389/fmed.2023.1212201. eCollection 2023.
9
"Super" SERPINs-A stabilizing force against fibrinolysis in thromboinflammatory conditions.“超级”丝氨酸蛋白酶抑制剂——血栓炎症状态下对抗纤维蛋白溶解的稳定力量。
Front Cardiovasc Med. 2023 Apr 19;10:1146833. doi: 10.3389/fcvm.2023.1146833. eCollection 2023.
10
Effects of the circulating environment of COVID-19 on platelet and neutrophil behavior.新型冠状病毒循环环境对血小板和中性粒细胞功能的影响。
Front Immunol. 2023 Mar 14;14:1130288. doi: 10.3389/fimmu.2023.1130288. eCollection 2023.